ReviewFrontiers in cell and developmental biology2026
Glutamine metabolism and its roles in tumor radiotherapy by regulating DNA damage repair.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a conditionally essential amino acid that is required by tumor cells, glutamine serves as a key metabolic hub in tumor cells, functioning both as a carbon source for the tricarboxylic acid cycle and lipid synthesis and as a nitrogen source for amino acid and nucleotide biosynthesis. Cancer cells reprogram glutamine metabolism to enhance its uptake and utilization, thereby supporting anabolic demands, maintaining redox homeostasis, and ensuring genomic stability. The efficacy of radiotherapy against malignancies largely depends on tumor cell radiosensitivity, which is influenced by DNA damage repair capacity, microenvironmental hypoxia, and cancer stem cells. Growing evidence indicates that glutamine metabolism significantly modulates tumor radiosensitivity by regulating the supply of key substrates for DNA damage repair, affecting repair protein function through post-translational modifications, and altering chromatin architecture. Methods: We performed a comprehensive literature search across PubMed and Web of Science, focusing on studies investigating the interplay among glutamine metabolism, DNA damage response, and tumor radiosensitivity. Based on critical analysis and synthesis of the retrieved literature, we propose an integrated framework linking metabolic rewiring to DNA repair modulation in the context of radiotherapy. Results: This review identifies three principal mechanisms by which glutamine metabolism may regulate the DNA damage response in tumors: (1) supplying essential substrates for DNA repair, including purines and pyrimidines derived from glutamine-dependent biosynthesis; (2) modulating the activity and function of DNA repair proteins through O-GlcNAcylation and PARylation as critical post-translational modifications, as well as regulating chromatin accessibility via histone modifications; and (3) maintaining redox homeostasis and counteracting iron-dependent lipid peroxidation to modulate ferroptosis susceptibility following irradiation. Notably, targeted inhibition of glutamine metabolism significantly enhances tumor radiosensitivity and suppresses tumor growth, demonstrating the therapeutic potential of metabolic intervention. Conclusion: Glutamine metabolism plays a multifaceted role in regulating the DNA damage response and tumor radiosensitivity. Targeting glutamine metabolic pathways, particularly through substrate supply deprivation, post-translational modification interference, or chromatin remodeling modulation, may represent a rational strategy for radiosensitization. This review provides a theoretical basis for the development of novel combination regimens integrating glutamine metabolism inhibitors with radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.